Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case
Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.
Authors
- Peter S. Amenta (ORCID: https://orcid.org/0000-0002-1500-7921)
- Rrita Daci (ORCID: https://orcid.org/0000-0003-3767-2284)
- Constance J. Mietus
- Mark D. Johnson (ORCID: https://orcid.org/0000-0002-4010-2605)
- Janelle P. Renterghem
- Cristina Hayes Meizoso
- David Cachia
- Brittany Owusu- Adjei
Institutions
- UMass Memorial Health Care (US)
- University of Massachusetts Chan Medical School (US)
- Worcester Memorial Hospital (US)
- Memorial Medical Center (US)
Publication Details
- Journal
- Journal of Neurosurgery Case Lessons
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3171/case25572
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00